JAC Advance Access published online on May 30, 2006
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkl217
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Healthcare-Associated Infection and Antimicrobial Resistance Department, Health Protection Agency Centre for Infections, 61 Colindale Avenue, London NW9 5EQ, UK
* To whom correspondence should be addressed. Objectives: To investigate the molecular epidemiology of Enterobacteriaceae producing extended- spectrum Methods: A prospective study involving 16 hospital microbiology laboratories in London and South-East England was undertaken over a 12 week period. Each laboratory submitted up to 100 consecutive cephalosporin-resistant Enterobacteriaceae isolates judged clinically significant by microbiology staff. Centralized testing was undertaken to confirm organism identification and cephalosporin resistance and to analyse resistance mechanisms. Results: The predominant mechanism of cephalosporin resistance in isolates from both hospital and community settings was the production of CTX-M-type ESBLs, with CTX-M-producing Escherichia coli as the most numerous resistant organism overall. Other major mechanisms of cephalosporin resistance included production of non-CTX-M ESBLs and AmpC Conclusions: CTX-M enzymes, which were unrecorded in the UK prior to 2000, have become the major mechanism of cephalosporin resistance in Enterobacteriaceae in South-East England. E. coli has overtaken Klebsiella and Enterobacter spp. to become the major host for ESBLs. Due to the multiple antibiotic resistance exhibited by many ESBL-producers, these changes have major implications for antimicrobial therapy.
Received January 20, 2006
Revised May 5, 2006
Accepted May 8, 2006
Original article
Prevalence and mechanisms of cephalosporin resistance in Enterobacteriaceae in London and South-East England
Nicola A. C. Potz 1 *,
Russell Hope 2,
Marina Warner 2,
Alan P. Johnson 1,
David M. Livermore 2,
and
on behalf of the London & South East ESBL Project Group
2 Antibiotic Resistance Monitoring and Reference Laboratory, Health Protection Agency Centre for Infections, 61 Colindale Avenue, London NW9 5EQ, UK
Nicola A. C. Potz, E-mail: nicola.potz{at}HPA.org.uk
![]()
Abstract
-lactamases (ESBLs) in London and South-East England.
-lactamases. Most ESBL (both CTX-M and non- CTX-M) producers were multiply resistant to non-
-lactam antibiotics, including trimethoprim, ciprofloxacin and gentamicin.![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
G. G. Zhanel, P. J. Baudry, F. Tailor, L. Cox, D. J. Hoban, and J. A. Karlowsky Determination of the pharmacodynamic activity of clinically achievable tigecycline serum concentrations against clinical isolates of Escherichia coli with extended-spectrum {beta}-lactamases, AmpC {beta}-lactamases and reduced susceptibility to carbapenems using an in vitro model J. Antimicrob. Chemother., October 1, 2009; 64(4): 824 - 828. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. J. Rooney, M. C. O'Leary, A. C. Loughrey, M. McCalmont, B. Smyth, P. Donaghy, M. Badri, N. Woodford, E. Karisik, and D. M. Livermore Nursing homes as a reservoir of extended-spectrum {beta}-lactamase (ESBL)-producing ciprofloxacin-resistant Escherichia coli J. Antimicrob. Chemother., September 1, 2009; 64(3): 635 - 641. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M. Livermore, S. Mushtaq, and M. Warner Activity of the anti-MRSA carbapenem razupenem (PTZ601) against Enterobacteriaceae with defined resistance mechanisms J. Antimicrob. Chemother., August 1, 2009; 64(2): 330 - 335. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. A. Jacoby AmpC {beta}-Lactamases Clin. Microbiol. Rev., January 1, 2009; 22(1): 161 - 182. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Pillar, M. K. Torres, N. P. Brown, D. Shah, and D. F. Sahm In Vitro Activity of Doripenem, a Carbapenem for the Treatment of Challenging Infections Caused by Gram-Negative Bacteria, against Recent Clinical Isolates from the United States Antimicrob. Agents Chemother., December 1, 2008; 52(12): 4388 - 4399. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Qin, D. M. Zerr, S. J. Weissman, J. A. Englund, D. M. Denno, E. J. Klein, P. I. Tarr, J. Kwong, J. R. Stapp, L. G. Tulloch, et al. Prevalence and Mechanisms of Broad-Spectrum {beta}-Lactam Resistance in Enterobacteriaceae: a Children's Hospital Experience Antimicrob. Agents Chemother., November 1, 2008; 52(11): 3909 - 3914. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. J. Baudry, K. Nichol, M. DeCorby, L. Mataseje, M. R. Mulvey, D. J. Hoban, and G. G. Zhanel Comparison of Antimicrobial Resistance Profiles among Extended-Spectrum-{beta}-Lactamase-Producing and Acquired AmpC {beta}-Lactamase-Producing Escherichia coli Isolates from Canadian Intensive Care Units Antimicrob. Agents Chemother., May 1, 2008; 52(5): 1846 - 1849. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-Y. Madec, C. Lazizzera, P. Chatre, D. Meunier, S. Martin, G. Lepage, M.-F. Menard, P. Lebreton, and T. Rambaud Prevalence of Fecal Carriage of Acquired Expanded-Spectrum Cephalosporin Resistance in Enterobacteriaceae Strains from Cattle in France J. Clin. Microbiol., April 1, 2008; 46(4): 1566 - 1567. [Full Text] [PDF] |
||||
![]() |
Risks of extended-spectrum beta-lactamases DTB, March 1, 2008; 46(3): 21 - 24. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Mammeri, F. Eb, A. Berkani, and P. Nordmann Molecular characterization of AmpC-producing Escherichia coli clinical isolates recovered in a French hospital J. Antimicrob. Chemother., March 1, 2008; 61(3): 498 - 503. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Mushtaq, R. Hope, M. Warner, and D. M. Livermore Activity of faropenem against cephalosporin-resistant Enterobacteriaceae J. Antimicrob. Chemother., May 1, 2007; 59(5): 1025 - 1030. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. M. Ensor, D. M. Livermore, and P. M. Hawkey A novel reverse-line hybridization assay for identifying genotypes of CTX-M-type extended-spectrum {beta}-lactamases J. Antimicrob. Chemother., March 1, 2007; 59(3): 387 - 395. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M. Livermore, R. Canton, M. Gniadkowski, P. Nordmann, G. M. Rossolini, G. Arlet, J. Ayala, T. M. Coque, I. Kern-Zdanowicz, F. Luzzaro, et al. CTX-M: changing the face of ESBLs in Europe J. Antimicrob. Chemother., February 1, 2007; 59(2): 165 - 174. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Hope, N. A. C. Potz, M. Warner, E. J. Fagan, E. Arnold, and D. M. Livermore Efficacy of practised screening methods for detection of cephalosporin-resistant Enterobacteriaceae J. Antimicrob. Chemother., January 1, 2007; 59(1): 110 - 113. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Woodford, S. Reddy, E. J. Fagan, R. L. R. Hill, K. L. Hopkins, M. E. Kaufmann, J. Kistler, M.-F. I. Palepou, R. Pike, M. E. Ward, et al. Wide geographic spread of diverse acquired AmpC {beta}-lactamases among Escherichia coli and Klebsiella spp. in the UK and Ireland J. Antimicrob. Chemother., January 1, 2007; 59(1): 102 - 105. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Hope, M. Warner, N. A. C. Potz, E. J. Fagan, D. James, and D. M. Livermore Activity of tigecycline against ESBL-producing and AmpC-hyperproducing Enterobacteriaceae from South-East England J. Antimicrob. Chemother., December 1, 2006; 58(6): 1312 - 1314. [Full Text] [PDF] |
||||




